171 related articles for article (PubMed ID: 9303410)
1. In vitro activity of trovafloxacin against Chlamydia pneumoniae.
Roblin PM; Kutlin A; Hammerschlag MR
Antimicrob Agents Chemother; 1997 Sep; 41(9):2033-4. PubMed ID: 9303410
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.
Roblin PM; Hammerschlag MR
Antimicrob Agents Chemother; 1998 Apr; 42(4):951-2. PubMed ID: 9559818
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae.
Roblin PM; Reznik T; Kutlin A; Hammerschlag MR
Antimicrob Agents Chemother; 1999 Nov; 43(11):2806-7. PubMed ID: 10543770
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.
Hammerschlag MR; Qumei KK; Roblin PM
Antimicrob Agents Chemother; 1992 Jul; 36(7):1573-4. PubMed ID: 1324650
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin.
Gikas A; Spyridaki I; Psaroulaki A; Kofterithis D; Tselentis Y
Antimicrob Agents Chemother; 1998 Oct; 42(10):2747-8. PubMed ID: 9756789
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae.
Roblin PM; Montalban G; Hammerschlag MR
Antimicrob Agents Chemother; 1994 Jun; 38(6):1402-3. PubMed ID: 8092845
[TBL] [Abstract][Full Text] [Related]
7. Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).
Kenny GE; Cartwright FD
Antimicrob Agents Chemother; 1996 Apr; 40(4):1048-9. PubMed ID: 8849228
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of trovafloxacin compared to those of five antimicrobials against mycoplasmas including Mycoplasma hominis and Ureaplasma urealyticum fluoroquinolone-resistant isolates that have been genetically characterized.
Bebear CM; Renaudin H; Charron A; Gruson D; Lefrancois M; Bebear C
Antimicrob Agents Chemother; 2000 Sep; 44(9):2557-60. PubMed ID: 10952617
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe.
Critchley IA; Jones ME; Heinze PD; Hubbard D; Engler HD; Evangelista AT; Thornsberry C; Karlowsky JA; Sahm DF
Clin Microbiol Infect; 2002 Apr; 8(4):214-21. PubMed ID: 12047413
[TBL] [Abstract][Full Text] [Related]
10. In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae.
Welsh L; Gaydos C; Quinn TC
Antimicrob Agents Chemother; 1996 Jan; 40(1):212-4. PubMed ID: 8787907
[TBL] [Abstract][Full Text] [Related]
11. The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.
Wise R; Brenwald NP; Andrews JM; Boswell F
J Antimicrob Chemother; 1997 Apr; 39(4):447-52. PubMed ID: 9145816
[TBL] [Abstract][Full Text] [Related]
12. The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae.
Hammerschlag MR; Roblin PM
J Antimicrob Chemother; 2004 Jul; 54(1):281-2. PubMed ID: 15190026
[No Abstract] [Full Text] [Related]
13. In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae.
Kuo CC; Jackson LA; Lee A; Grayston JT
Antimicrob Agents Chemother; 1996 Nov; 40(11):2669-70. PubMed ID: 8913488
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility of Chlamydia trachomatis to trovafloxacin.
Jones RB; Van der Pol B; Johnson RB
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():63-5. PubMed ID: 9222072
[TBL] [Abstract][Full Text] [Related]
15. In-vitro activity of gatifloxacin against Chlamydia trachomatis and Chlamydia pneumoniae.
Roblin PM; Hammerschlag MR
J Antimicrob Chemother; 1999 Oct; 44(4):549-51. PubMed ID: 10588319
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.
Roblin PM; Reznik T; Kutlin A; Hammerschlag MR
Antimicrob Agents Chemother; 2003 Mar; 47(3):1135-6. PubMed ID: 12604555
[TBL] [Abstract][Full Text] [Related]
17. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates.
Felmingham D; Robbins MJ; Ingley K; Mathias I; Bhogal H; Leakey A; Ridgway GL; Grüneberg RN
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():43-9. PubMed ID: 9222069
[TBL] [Abstract][Full Text] [Related]
18. In vitro activities of azithromycin and doxycycline against 15 isolates of Chlamydia pneumoniae.
Gnarpe J; Eriksson K; Gnarpe H
Antimicrob Agents Chemother; 1996 Aug; 40(8):1843-5. PubMed ID: 8843291
[TBL] [Abstract][Full Text] [Related]
19. Comparative in vitro activities of four new fluoroquinolones against Streptococcus pneumoniae determined by Etest.
Waites K; Brookings E; Nix S; Robinson A; Gray B; Swiatlo E
Int J Antimicrob Agents; 1998 Feb; 9(4):215-8. PubMed ID: 9573490
[TBL] [Abstract][Full Text] [Related]
20. Comparative antimicrobial activity of trovafloxacin tested against 3049 Streptococcus pneumoniae isolates from the 1997-1998 respiratory infection season.
Jones RN; Pfaller MA; Doern GV
Diagn Microbiol Infect Dis; 1998 Oct; 32(2):119-26. PubMed ID: 9823536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
